CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
The new online Learning Center with new content can still be found under the “Training” folder on ...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...